Synthesis, DNA-Binding, Anticancer Evaluation, and Molecular Docking Studies of Bishomoleptic and Trisheteroleptic Ru-Diimine Complexes Bearing 2-(2-Pyridyl)-quinoxaline.

Bioinorganic Chemistry and Applications
Sofia BalouChristiana A Mitsopoulou

Abstract

Herein, we report the synthesis and characterization of a bishomoleptic and a trisheteroleptic ruthenium (II) polypyridyl complex, namely, [Ru(bpy)2(2, 2'-pq)](PF6)2 (1) and [Ru(bpy) (phen) (2, 2'-pq)](PF6)2 (2), respectively, where bpy = 2,2'-bipyridine, phen = 1,10-phenanthroline, and 2, 2'-pq = 2-(2'-pyridyl)-quinoxaline. The complexes were characterized by elemental analysis, TGA, 1H-NMR, FT-IR, UV-Vis, emission spectroscopy, and electrochemistry. Their structures were confirmed by single-crystal X-ray diffraction analysis. Complexes 1 and 2 were crystalized in orthorhombic, Pbca, and monoclinic, P21/n systems, respectively. Various spectroscopic techniques were employed to investigate the interaction of both complexes with calf thymus DNA (CT-DNA). The experimental data were confirmed by molecular docking studies, employing two different DNA sequences. Both complexes, 1 and 2, bind with DNA via a minor groove mode of binding. MTT experiments revealed that both complexes induce apoptosis of MCF-7 (breast cancer) cells in low concentrations. Confocal microscopy indicated that 2 localizes in the nucleus and internalizes more efficiently in MCF-7 than in HEK-293.

References

Oct 7, 2004·Biophysical Journal·Nichola C GarbettDavid E Graves
Dec 17, 2005·Dalton Transactions : an International Journal of Inorganic Chemistry·Declan MulhernJohannes G Vos
Sep 11, 2007·Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy·Chunyu QiaoWeihong Zhou
Dec 15, 2007·Nature Protocols·Nichola C GarbettJonathan B Chaires
Dec 25, 2007·Acta Crystallographica. Section A, Foundations of Crystallography·George M Sheldrick
Dec 22, 2009·Dalton Transactions : an International Journal of Inorganic Chemistry·Carlos Sánchez-Cano, Michael J Hannon
Jul 17, 2010·Bioinorganic Chemistry and Applications·Christiana A Mitsopoulou, Constantinos Dagas
Jul 12, 2014·European Journal of Medicinal Chemistry·Joana A PereiraMónica Vieira
Jan 22, 2015·Dalton Transactions : an International Journal of Inorganic Chemistry·Guoliang LiaoHui Chao
Jul 19, 2016·Dalton Transactions : an International Journal of Inorganic Chemistry·Guanying LiHui Chao
Nov 4, 2016·Chemical Society Reviews·Yong-Jun YuanZhi-Gang Zou
Jan 12, 2017·Dalton Transactions : an International Journal of Inorganic Chemistry·Konstantinos YpsilantisAchilleas Garoufis
Jan 14, 2017·Chemical Society Reviews·Noémie ElgrishiMarc Fontecave
Dec 6, 2017·European Journal of Medicinal Chemistry·Sana TariqMohd Amir
Dec 7, 2018·Bioorganic & Medicinal Chemistry·Tanu KaushalArvind Singh Negi
Sep 27, 2019·Dalton Transactions : an International Journal of Inorganic Chemistry·Monize M da SilvaAlzir A Batista
Oct 1, 2019·Nucleosides, Nucleotides & Nucleic Acids·Hong-Ju YinKe-Zhi Wang
Mar 29, 2020·Journal of Biomolecular Structure & Dynamics·Selvan NehruSankaralingam Arunachalam

❮ Previous
Next ❯

Software Mentioned

AutoDock4
Olex2
Mercury
SHELXT
AutoGrid4
MGL

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Breast Cancer: Therapeutic Approaches

Several different therapeutic approaches are used to treat breast cancer. These include chemotherapy, hormonal therapy, targeted therapy, and Immunotherapy. Discover the latest research on breast cancer therapeutic approaches here.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis